Portuguese-American physician Filipa Lynce, MD, has been recognized as a Top Doctor in Boston for 2025. She is among more than 145 physicians affiliated with Dana-Farber Cancer Institute honored in Boston magazine’s annual Top Doctors guide.

In addition to this recognition, Dr. Lynce has been listed as a Castle Connolly Top Doctor since 2022.

Dr. Lynce is a medical oncologist specializing in breast oncology at Dana-Farber Cancer Institute, where she serves as the Director of the Inflammatory Breast Cancer Program. She is also an Assistant Professor of Medicine at Harvard Medical School.

Her clinical interests include BRCA-associated breast cancers, inflammatory breast cancer, triple-negative breast cancer, and the development of novel therapies for breast cancer.

Board-certified in Internal Medicine, Hematology, and Medical Oncology, Dr. Lynce earned her medical degree in 2004 from Universidade Nova de Lisboa in Portugal, followed by residency and fellowship training at MedStar Washington Hospital Center/MedStar Georgetown University Hospital in Washington, D.C.

From 2015 to 2020, she was a faculty member at MedStar Georgetown University Hospital, where she served as the institutional principal investigator for the Alliance for Clinical Trials in Oncology and co-principal investigator for the National Capital Area (NCA) Minority/Underserved NCORP.

In 2020, Dr. Lynce joined Dana-Farber Cancer Institute and Brigham and Women’s Hospital, where she continues to focus on clinical research and patient care in breast oncology. Her research explores inflammatory breast cancer, triple-negative breast cancer, BRCA-associated breast cancers, and novel therapies for breast cancer treatment.

Born in Portugal, Dr. Lynce is fluent in Portuguese and Spanish.

Source: Dana-Farber Cancer Institute